1 xt] The recent finding that the FDA-approved
antiobesity agent orlistat (tetrahydrolipstatin, Xenical
2 Preliminary evidence suggests that the
antiobesity agent sibutramine is effective in the treatm
3 a pentacyclic triterpene, is the most potent
antiobesity agent that has been reported thus far(1).
4 814580 (compound 10) as a highly efficacious
antiobesity agent with a relatively clean in vitro and i
5 6 would therefore have great potential as an
antiobesity agent.
6 a) are widely considered to offer utility as
antiobesity agents by lowering the set-point for hunger
7 ty profile to support clinical evaluation as
antiobesity agents has been a challenge.
8 Successful development of
antiobesity agents requires detailed knowledge of neural
9 heterodimer, with implications for potential
antiobesity agents that target centrally coexpressed Y1
10 t Y5 antagonists for evaluation as potential
antiobesity agents, a pharmacophore model for the human
11 a new class of dual-acting hypolipidemic and
antiobesity agents.
12 one-containing, selective 5-HT2C agonists as
antiobesity agents.
13 hrelin are unlikely to have broad utility as
antiobesity agents.
14 antagonists are currently being developed as
antiobesity and antidepressant drugs.
15 Because currently available
antiobesity and antidiabetic drugs have limited efficacy
16 R blockade may allow safely potentiating the
antiobesity and antidiabetic effects of currently availa
17 Because resulting beige/brite cells exhibit
antiobesity and antidiabetic effects, nitrate may be an
18 ilities for future development of successful
antiobesity and antidiabetic therapies.
19 These results identify Rb1 as an
antiobesity and antihyperglycemic agent.
20 antimicrobial, antidiabetic, antioxidative,
antiobesity and antihypertensive effects.
21 so shown that neddylation inhibitors possess
antiobesity and hypoglycemic property.
22 ll persist or decline in the future as newer
antiobesity and MASLD-related drugs are increasingly use
23 antioxidant, anti-inflammatory, anticancer,
antiobesity,
and antifungal activities, are primarily at
24 ation was required to achieve the lipolytic,
antiobesity,
and metabolic effects of PDE9-I.
25 antidiabetic, antihypertensive, anticancer,
antiobesity,
antihyperlipidemic, and anti-inflammatory p
26 ome-related activities such as antidiabetic,
antiobesity,
antihypertensive, and antioxidative propert
27 an inhibition that appears to be due to the "
antiobesity,"
antihypertriglyceridemic, and antiinflamma
28 The coextract exhibited high antidiabetic,
antiobesity,
antimelanogenesis, anti-inflammatory, and a
29 ors that show biased agonism and potentially
antiobesity behavior via a new mechanism.
30 alinolamide (6) were investigated in mice as
antiobesity compounds.
31 (CB1) have been demonstrated to be anorectic
antiobesity drug candidates.
32 ights this circuit as a promising target for
antiobesity drug development.
33 utility is demonstrated in the synthesis of
antiobesity drug Rimonabant and anti-HIV agent PNU-32945
34 nsferases; these may provide new targets for
antiobesity drug therapy.
35 Orlistat, an
antiobesity drug, is cytostatic and cytotoxic to tumor c
36 ptide receptor 1 (GLP-1R) agonist used as an
antiobesity drug.
37 Unless effective
antiobesity drugs are developed, the effect of obesity o
38 Among the 4
antiobesity drugs currently approved for pediatric use,
39 of Pediatrics has recommended treatment with
antiobesity drugs for adolescents, the cost-effectivenes
40 s for adolescents, the cost-effectiveness of
antiobesity drugs for this population is still unknown.
41 Antiobesity drugs orlistat, liraglutide, semaglutide, an
42 In this review, we will discuss the
antiobesity drugs with Food and Drug Administration appr
43 h for 5-HT2CR allosteric modulators as safer
antiobesity drugs, a chemical library from Vivia Biotech
44 been the target of potential anxiolytics and
antiobesity drugs, and its positive allosteric modulator
45 d with the stringent safety requirements for
antiobesity drugs, highlight the importance of incorpora
46 Despite the recent failures of a number of
antiobesity drugs, the pharmacotherapy of obesity is pro
47 g a new chemical entity for the discovery of
antiobesity drugs.
48 s of Y4 receptors and as a lead compound for
antiobesity drugs.
49 ay be a valuable target for developing novel
antiobesity drugs.
50 ol over fat intake and might be a target for
antiobesity drugs.
51 therefore have potential for development as
antiobesity drugs.
52 eptor antagonists with the aim of developing
antiobesity drugs.
53 ) receptor agonists (GLP-1RAs) are effective
antiobesity drugs.
54 This
antiobesity effect is attributed to an increase in the t
55 This remarkable yet paradoxical
antiobesity effect is suggested to occur primarily via t
56 parable to DIO, proving the MC4R-independent
antiobesity effect of celastrol.
57 suggest that in ob/ob mice, the antidiabetic
antiobesity effect of leptin could be the result of a pr
58 sis and acts as a downstream mediator of the
antiobesity effect of pan neddylation inhibitors.
59 ed risk of obesity but the mechanism for the
antiobesity effect of standing is unknown.
60 oraphane, supporting the conclusion that the
antiobesity effect of sulforaphane requires functional l
61 n-3 long-chain PUFAs (LC-PUFAs) may exert an
antiobesity effect.
62 nists alters energy balance and has a marked
antiobesity effect.
63 Remarkably, the vast majority of leptin's
antiobesity effects are mediated by GABAergic neurons; g
64 hanism of celastrol's leptin-sensitizing and
antiobesity effects has not yet been elucidated.
65 The
antiobesity effects of DualAG require activation of both
66 The
antiobesity effects of ER-beta ligand were not observed
67 The recent publications of anorectic and
antiobesity effects of the first two selective MCH1-R an
68 Hypolipidemic and
antiobesity effects of the newly synthesized indole-base
69 robably mediates, at least in part, leptin's
antiobesity effects.
70 invalidates rodent models for assessing the
antiobesity efficacy of 14G: and 14H: .
71 th a diagnosis of obesity and evidence of an
antiobesity GLP1R prescription or lifestyle intervention
72 2 adolescents with obesity and a concomitant
antiobesity intervention were identified for the GLP1R c
73 We compared the effects of targeting
antiobesity interventions at the most connected individu
74 ogy of obesity and availability of effective
antiobesity interventions has developed rapidly.
75 Proposed
antiobesity mechanisms of CLA include regulation of (a)
76 cians, and counselors, as well as prescribed
antiobesity medication and monitored closely for weight
77 Antiobesity medication management includes selecting med
78 There were no between-group differences in
antiobesity medication prescribing.
79 weight loss, referral to WMTs, and number of
antiobesity medication prescriptions at 12 months.
80 takes advantage of specific features of the
antiobesity medication selected to provide the best opti
81 Inclusion criteria were no prior
antiobesity medication, GLP-1, bariatric surgery, or dia
82 l consideration of its development as a safe
antiobesity medication.
83 ing, very low-calorie meal replacement (MR),
antiobesity medications (AOM), and bariatric surgery; ho
84 The clinical efficacy of
antiobesity medications (AOMs) as adjuncts to lifestyle
85 Recent publicity around the use of new
antiobesity medications (AOMs) has focused the attention
86 ance to improve health, but highly effective
antiobesity medications (AOMs) have recently become avai
87 Antiobesity medications (AOMs) modify biological process
88 Antiobesity medications are effective adjunctive therapy
89 Antiobesity medications are intended for long-term use g
90 In addition,
antiobesity medications are meant to be used in conjunct
91 , but severe adverse events from these newer
antiobesity medications are rare.
92 Antiobesity medications are recommended for nonpregnant
93 the risks and benefits of the full range of
antiobesity medications available to patients, and to in
94 With the increasing number of
antiobesity medications available, the treatment of obes
95 ons available, the treatment of obesity with
antiobesity medications may increase the pool of potenti
96 The tremendous variability in response to
antiobesity medications means that clinicians need to us
97 iasthma medication albuterol sulfate and the
antiobesity medications orlistat, phentermine hydrochlor
98 ical guidelines support the use of long-term
antiobesity medications when weight maintenance is inade
99 istory of bariatric procedures, taking other
antiobesity medications, and with an active malignant ne
100 Novel
antiobesity medications, particularly glucagon-like pept
101 Newer
antiobesity medications, such as liraglutide, semaglutid
102 avioral modification, bariatric surgery, and
antiobesity medications.
103 ion therapies, and the cost effectiveness of
antiobesity medications.
104 The feasibility of performing any primary
antiobesity operation safely laparoscopically was convin
105 ptamine, 5-HT) efficacy has been a target of
antiobesity pharmacotherapies.
106 Antiobesity pharmacotherapy is recommended for adolescen
107 We identified an
antiobesity phenotype of EC-AGO1-KO, evident by lower bo
108 ile synthetic agonists activating BRS-3 show
antiobesity profiles by inhibiting food intake and incre
109 This review examines whether CLA's
antiobesity properties are due to inflammatory signaling
110 NO in vivo and demonstrates antidiabetic and
antiobesity properties in rodents.
111 ympathetic nervous system in mediating CLA's
antiobesity properties.
112 Both systems are exploited clinically as
antiobesity strategies.
113 These results identify KE as a potential
antiobesity supplement.
114 However,
antiobesity surgery entails very much more than techniqu
115 were most types of gastrointestinal surgery,
antiobesity surgery was dominated by the development of
116 -up, and devising strategies for reoperative
antiobesity surgery.
117 ompounds for the anticancer target CA IX and
antiobesity target CA VB.
118 ising the possibility of using Syt4 as a new
antiobesity target.
119 he context of efforts to develop GDF15 as an
antiobesity therapeutic, these findings identify a bioma
120 rapeutic avenues at the dawn of a new era of
antiobesity therapeutics.
121 GAT as a potential point of intervention for
antiobesity therapies.
122 Here, we report an
antiobesity therapy based on targeted induction of apopt
123 Aldh1 is a potential target for sex-specific
antiobesity therapy.
124 AT) because of its potential utilization for
antiobesity therapy.
125 ocytes and may constitute a novel target for
antiobesity therapy.
126 A) is being developed as an antidiabetes and
antiobesity treatment due to its potent and specific inh
127 ase the effectiveness of MC4R agonists as an
antiobesity treatment.
128 us, this combination therapy may be a viable
antiobesity treatment.